NCT03983668View on ClinicalTrials.gov

CMP-001 for Relapsed and Refractory Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

August 23, 2024

Study Completion Date

April 8, 2025

Conditions

Lymphoma

Interventions

DRUG

CMP-001

Immunostimulatory therapeutic agent

DRUG

Pembrolizumab

Humanized antibody used in cancer immunotherapy

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

Checkmate Pharmaceuticals

All Listed Sponsors

collaborator

Checkmate Pharmaceuticals

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

University of Iowa

OTHER

lead

Umar Farooq

OTHER